Healthcare
Satellos Bioscience Inc.(MSCLF)
Live Price
Offline$6.25
+11.81% today
Window Change
+17.95%
Window
Jun 23, 2025 โ Apr 6, 2026
- Market Cap
- $96.62M
- Revenue Growth
- 0.0%
- EPS Growth
- -679900.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars ยท Jun 23, 2025 โ Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Satellos Bioscience Inc. (MSCLF) is a Healthcare stock with a market cap of $96.62M and listed on OTC. The stock last traded around $6.25 and up 18.0% across the available one-year price window (Jun 23, 2025 โ Apr 6, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -679900.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -679900.0%, free cash flow +5.5% with operating margin 0.0% and ROIC -20.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MSCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 27, 2026 with an EPS surprise of -14131.9%.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -679900.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 27, 2026 | -14131.9% | -4.5% | -8.7% | โ |
2025 Nov 14, 2025 | -10.3% | +9.7% | -1.8% | -5.7% |
2025 Aug 13, 2025 | +10.6% | +1.8% | -0.6% | +23.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
MSCLF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
MSCLF Max Drawdown
-56.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MSCLF and SPY.
Company Overview
Satellos Bioscience Inc.
Other OTC
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
- Leadership
- Francis Gleeson
- IPO Date
- Aug 3, 2012
- Employees
- 14
- Street Address
- 65 Front Street East
- Mailing
- Toronto, ON, M5E 1B5
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 647 660 1780
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.5
Growth
- Revenue
- 0.0%
- EPS
- -679900.0%
- Free Cash Flow
- +5.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -51.4%
- ROIC
- -20.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 11.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.